Skip to main content

Table 1 Study population baseline demographic and surgical characteristics

From: Prophylactic use of levosimendan in pediatric patients undergoing cardiac surgery: a prospective randomized controlled trial

Characteristics

Levosimendan group (n = 94)

Placebo group (n = 93)

p value

Age (months)a

5 (2,11)

7 (2,16)

0.318

Gender, female, n (%)

42 (44.7%)

41 (44.1%)

1.000

BMI (kg/m2)

14.83 ± 2.21

14.76 ± 2.13

0.870

BSA (m2)

0.36 ± 0.17

0.39 ± 0.19

0.248

RACHS classification, n (%)*

  

0.146

 RACHS 2

53 (63.1%)

67 (72.0%)

 

 RACHS 3

21 (25.0%)

11 (11.8%)

 

 RACHS 4

9 (10.7%)

13 (14.0%)

 

 RACHS 5

1 (1.2%)

2 (2.2%)

 

Down’s syndrome, n (%)

3 (3.2%)

2 (2.2%)

0.660

CPB (min)

81 ± 34

84 ± 30

0.479

Cross-clamp (min)

46 ± 23

51 ± 22

0.163

  1. Data are means ± standard deviation (SD) for continuous variables and number of subjects (n) and percentage (%) for categorical variables
  2. BSA body surface area, RACHS Risk Adjustment for Congenital Heart Surgery, CPB cardiopulmonary bypass, BMI body mass index
  3. aData are medians [Q1, Q3]
  4. *RACHS classification was used to divide surgical procedures for congenital heart diseases into six categories of increasing predicted operative risk. The greater the score, the higher the risk associated with the procedure